These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38037900)

  • 41. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM).
    Pedrazzoli P; Lasagna A; Cassaniti I; Ferrari A; Bergami F; Silvestris N; Sapuppo E; Di Maio M; Cinieri S; Baldanti F
    ESMO Open; 2022 Aug; 7(4):100548. PubMed ID: 35853350
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
    Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.
    L'Huillier AG; Hirzel C; Ferreira VH; Ierullo M; Ku T; Selzner N; Schiff J; Juvet S; Miao C; Schmid DS; Humar A; Kumar D
    Transplantation; 2021 Oct; 105(10):2316-2323. PubMed ID: 33528118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Th1 memory differentiates recombinant from live herpes zoster vaccines.
    Levin MJ; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Weinberg A
    J Clin Invest; 2018 Oct; 128(10):4429-4440. PubMed ID: 30024861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
    Berkowitz EM; Moyle G; Stellbrink HJ; Schürmann D; Kegg S; Stoll M; El Idrissi M; Oostvogels L; Heineman TC;
    J Infect Dis; 2015 Apr; 211(8):1279-87. PubMed ID: 25371534
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
    Ali SO; Dessart C; Parikh R
    Vaccine; 2024 Mar; 42(8):2026-2035. PubMed ID: 38423814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding the immunology of Shingrix, a recombinant glycoprotein E adjuvanted herpes zoster vaccine.
    Heineman TC; Cunningham A; Levin M
    Curr Opin Immunol; 2019 Aug; 59():42-48. PubMed ID: 31003070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age.
    Chlibek R; Bayas JM; Collins H; de la Pinta ML; Ledent E; Mols JF; Heineman TC
    J Infect Dis; 2013 Dec; 208(12):1953-61. PubMed ID: 23904292
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
    Ocran-Appiah J; Boutry C; Hervé C; Soni J; Schuind A;
    Vaccine; 2021 Jan; 39(1):6-10. PubMed ID: 33277059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression.
    Losa L; Antonazzo IC; Di Martino G; Mazzaglia G; Tafuri S; Mantovani LG; Ferrara P
    Vaccines (Basel); 2024 May; 12(5):. PubMed ID: 38793778
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
    Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
    Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020.
    Orru' S; Bierbaum S; Enk A; Hengel H; Hoffelner M; Huzly D; Keller-Stanislawski B; Mahler V; Mockenhaupt M; Oberle D
    Euro Surveill; 2023 Dec; 28(50):. PubMed ID: 38099347
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine.
    Levin MJ; Weinberg A
    Clin Infect Dis; 2020 Mar; 70(7):1509-1515. PubMed ID: 31618437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.
    Cunningham AL; Heineman TC; Lal H; Godeaux O; Chlibek R; Hwang SJ; McElhaney JE; Vesikari T; Andrews C; Choi WS; Esen M; Ikematsu H; Choma MK; Pauksens K; Ravault S; Salaun B; Schwarz TF; Smetana J; Abeele CV; Van den Steen P; Vastiau I; Weckx LY; Levin MJ;
    J Infect Dis; 2018 May; 217(11):1750-1760. PubMed ID: 29529222
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials.
    Willer DO; Oostvogels L; Cunningham AL; Gervais P; Gorfinkel I; Hyung Kim J; Talarico C; Wascotte V; Zahaf T; Colindres R; Schuind A;
    Vaccine; 2019 Oct; 37(43):6262-6267. PubMed ID: 31537443
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Herpes Zoster and Its Prevention by Vaccination.
    Johnson RW; Levin MJ
    Interdiscip Top Gerontol Geriatr; 2020; 43():131-145. PubMed ID: 32305975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years.
    Leidner AJ; Anderson TC; Hong K; Ortega-Sanchez IR; Guo A; Pike J; Prosser LA; Dooling KL
    Value Health; 2023 Feb; 26(2):204-215. PubMed ID: 36243666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.